Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PSMA ADC - Progenics Pharmaceuticals

Drug Profile

PSMA ADC - Progenics Pharmaceuticals

Alternative Names: Monomethylauristatin E-antiPSMA monoclonal antibody conjugate; PSMA Antibody Drug Conjugate

Latest Information Update: 08 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PSMA Development Company
  • Developer Brown University; Progenics Pharmaceuticals; Rhode Island Hospital; University of Texas at Dallas
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioblastoma; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Feb 2018 Discontinued - Phase-II for Glioblastoma, Prostate cancer (First-line therapy, Hormone refractory, Metastatic disease) and Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (IV) (Not listed on Progenics pipeline, February 2018)
  • 09 Mar 2017 Progenics Pharmaceuticals has patent protection for PSMA ADC in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top